Universal Health Services (NYSE:UHS) posts Q3 2026 sales in line with estimates

Universal Health Services (UHS) reported Q3 2026 revenue of $4.73 billion, matching estimates and showing 5.3% year-on-year growth. Adjusted EPS beat estimates at $5.22, while adjusted EBITDA missed at $624.6 million. Operating margin declined to 9.6% from 11.6% year-on-year, but free cash flow margin improved to 8.9% from 3.4%. Same-store sales rose 4.7% year-on-year, up from 2% in the prior year quarter.

Original reporting
Published Oct 27, 2026, 8:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 8:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Universal Health Services (NYSE:UHS) posts Q3 2026 sales in line with estimates — source image
Decision brief

The 30-second read

$UHSNeutralHigh
01

Why it matters

The earnings release provides fresh data on revenue growth, profitability, and cash generation, which are key inputs for valuation models and short‑term trading decisions.

02

Market read

UHS earnings are the primary catalyst for the article, offering actionable insight for traders in the healthcare sector.

03

What to watch

The rise in same‑store sales (4.7% YoY) and improved free cash flow margin (8.9%) may support longer‑term upside.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Universal Health Services (UHS) is a leading provider of acute care and behavioral health services in the United States.

Company-level read

Ticker impact

$UHSNeutralHigh confidence
Context

Universal Health Services reported Q3 2026 revenue of $4.73B in line with estimates, EPS beat, but EBITDA missed expectations.

Expected impact

potential modest downside pressure as the market prices in the EBITDA miss despite the EPS beat

Evidence & confidence

The beat on adjusted EPS is modest (1.3%) while adjusted EBITDA fell short (1.6% miss) and operating margin declined, suggesting investors may focus on the profit margin weakness.

Market effects

Healthcare services sector may see scrutiny on margin trends across peers.

U.S. healthcare stocks could experience slight volatility in the post‑market session.

Limited to U.S. markets; no immediate global ripple.

Counterpoint

Investors could view the EPS beat as a sign of pricing power and buy on dip despite margin pressure.

Key entities

  • Universal Health Services

    U.S. healthcare services operator reporting Q3 2026 results.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$CNCMed

Health insurers, hospitals rally after sweeping midterm win for Democrats

Shares of Medicaid-focused health insurers (Centene, Elevance, Molina) and hospital operators (HCA, Tenet, Universal) rose after Democrats won the midterms, raising hopes for sector-friendly policies. Analysts expect delays in Trump's OBBBA, easing pressure on Medicaid and ACA insurers, and potential extensions of enhanced subsidies. Year-to-date gains vary among companies.

$UHSHighAI 8/10

Softer surgery volumes, hospital woes dampened UHS’ Q3 earnings

Universal Health Services (UHS) lowered its 2026 earnings expectations due to declining surgeries and struggles at some hospitals. Q3 net income fell 17% to $308M, while revenues rose 5% to $4.7B. Challenges include lower surgery volumes, delays in new hospital profitability, and rising uninsured patients. UHS expects to be at the lower end of its guidance range for 2024.

$UHSMed

Guggenheim cuts Universal Health Services stock price target to $201 on weak Q3

Guggenheim reduced its price target for Universal Health Services (UHS) to $201 from $209, citing weak Q3 2026 EBITDA and macro pressures. UHS stock is down 8.5% in a week. The company lowered its 2026 EBITDA guidance but sees potential upside from expansions. UHS reported Q3 EPS of $5.22 and revenue of $4.73B, slightly beating estimates. Raymond James kept a Market Perform rating, noting softer profit trends and a cautious 2027 outlook.